CGTX Surges on Oral GA Drug Data – Is the Market Overreacting or Catching On?

CGTX stock surged 29.56% after promising Phase 2 trial results for an oral treatment targeting geographic atrophy (GA)

Cognition Therapeutics Inc. (NASDAQ: CGTX) saw its stock spike by 29.56% in after-hours trading on May 9, 2025, closing at $0.39. The after-hours move was largely reactionary to clinical trial news, the stock’s low absolute share price and modest market cap of $18.66 million created fertile ground for speculative momentum. Catalyst: Topline Results for Oral … Read more